Trubion
{{Primary sources|date=May 2009}}
{{Infobox company
| name = Trubion
| logo = File:Trubion-logo.PNG
| type = Public company
| traded_as = {{NASDAQ was|TRBN}}|
foundation = 1999
| location = Seattle, WA
| key_people =
| fate = acquired by Emergent BioSolutions (2010)
| industry = Biopharmaceutical
| products = Protein-based therapeutics
| revenue =
| num_employees =
| homepage = [http://www.trubion.com www.trubion.com]
}}
Trubion was a publicly held biopharmaceutical company that was focused on creating a pipeline of protein-based therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. Trubion was acquired by Emergent BioSolutions on October 28, 2010.{{cite web |url=http://www.reuters.com/article/2010/10/28/idUS289053+28-Oct-2010+BW20101028 |title=Emergent BioSolutions Completes Acquisition of Trubion Pharmaceuticals | Reuters |website=www.reuters.com |access-date=13 January 2022 |archive-url=https://web.archive.org/web/20141205114344/http://www.reuters.com/article/2010/10/28/idUS289053+28-Oct-2010+BW20101028 |archive-date=5 December 2014 |url-status=dead}} Trubion was established in 1999 in the State of Washington as an early stage development company, and was later reincorporated in October 2002 in the State of Delaware.
In December 2005, Trubion entered into a collaborative agreement with Wyeth{{cite web |url=http://www.wyeth.com/cbd/history/casestudies/trubion |title=Wyeth.com | CBD - Trubion Alliance |accessdate=2008-07-30 |url-status=dead |archiveurl=https://web.archive.org/web/20080828124123/http://www.wyeth.com/cbd/history/casestudies/trubion |archivedate=2008-08-28 }} for the development and worldwide commercialization of CD20-directed therapeutics. The agreement also included the development and worldwide commercialization of certain other product candidates directed to targets other than CD20. The research portion of Trubion's contract with Wyeth extended through December 22, 2009.
Former product pipeline
| class="wikitable" |
| Name
! Platform ! Indication ! Status ! Collaboration ! Research |
|---|
| TRU-015
| SMIP | Phase 2b | Wyeth | Phase 2b initiationhttp://investors.trubion.com/releasedetail.cfm?ReleaseID=308846{{Dead link|date=July 2018 |bot=InternetArchiveBot |fix-attempted=no }} |
| SBI-087
| SMIP | Rheumatoid arthritis | Phase 1 | Wyeth |
| SBI-087
| SMIP | Systemic lupus erythematosus | Phase 1 | Wyeth | |
| TRU-016
| SMIP | Chronic lymphocytic leukemia | Phase 1/2 | Trubion Proprietary Technology |
| TRU-016
| SMIP | Pre-clinical | Trubion Proprietary Technology | |
| TRU-016
| SMIP | Autoimmune disease and inflammation | Pre-clinical | Trubion Proprietary Technology | |
Former technology
Trubion's product development efforts were focused on three technology pillars: SMIP protein therapeutics, SCORPION protein therapeutics, and TRU-ADhanCe potency enhancing technology for immunopharmaceuticals.
SMIP, or small modular immunopharmaceutical, therapeutics are single chain polypeptides comprising one binding domain, one hinge domain and one effector domain designed in an effort to meet predetermined therapeutic specifications for specific diseases. SMIP therapeutics are mono-specific (they recognize and attach to single antigen targets and initiate biological activity). Trubion worked on SMIP drug candidates that targeted validated antigens with the same specificity and predictable biological activity as mAbs.
SCORPION protein therapeutics are also single chain polypeptides composed of functional domains from naturally occurring proteins. The difference between SMIP and SCORPION technologies is that SCORPION compounds are multi-specific therapeutics that are capable of targeting two or more antigens simultaneously.
TRU-ADhanCe potency enhancing technology was designed to enhance the potency of existing therapies that work through Fc-directed or antibody-directed cellular cytotoxicity, or ADCC. TRU-ADhanCe technology could be applied late in development to established manufacturing lines and generate candidates with increased ADCC and longer in vivo half lives.
References
{{reflist}}
{{Pharmaceutical companies of the United States}}
Category:Biotechnology companies of the United States
Category:Defunct pharmaceutical companies of the United States
Category:Defunct companies based in Seattle
Category:Companies formerly listed on the Nasdaq
Category:Biotechnology companies established in 1999
Category:Biotechnology companies disestablished in 2010
Category:Pharmaceutical companies established in 1999
Category:Pharmaceutical companies disestablished in 2010
Category:1999 establishments in Washington (state)